Updating results

538 results

Sort: Relevance | Date

Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay) (DG18)

Evidence-based recommendations on procalcitonin testing for diagnosing and monitoring sepsis (AVIDA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive..

Diagnostics guidance Published October 2015

SeHCAT (tauroselcholic [75 selenium] acid) for the investigation of diarrhoea due to bile acid malabsorption in people with diarrhoea-predominant irritable bowel syndrome (IBS-D) or Crohn's disease without ileal resection (DG7)

Evidence-based recommendations on SeHCAT (tauroselcholic [75 selenium] acid) for investigating diarrhoea due to bile acid malabsorption (BAM)

Diagnostics guidance Published November 2012

Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (DG6)

Evidence-based recommendations on the Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M depth of anaesthesia monitors

Diagnostics guidance Published November 2012

SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (DG5)

Evidence-based recommendations on theSonoVue (sulphur hexafluoride microbubbles) contrast agent for contrast-enhanced ultrasound imaging of the liver

Diagnostics guidance Published August 2012

Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis (DG36)

Evidence-based recommendations on enzyme-linked immunosorbent assay (ELISA) tests for therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis

Diagnostics guidance Published July 2019

Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care (DG35)

Evidence-based recommendations on lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care

Diagnostics guidance Published May 2019

Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34)

Evidence-based recommendations on tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer

Diagnostics guidance Published December 2018

Biomarker tests to help diagnose preterm labour in women with intact membranes (DG33)

Evidence-based recommendations on biomarker tests (Actim Partus, PartoSure, Rapid fFN 10Q Cassette) to diagnose preterm labour in women with intact membranes

Diagnostics guidance Published July 2018

Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I (DG32)

Evidence-based recommendations on DYSIS colposcope with DYSISmap and ZedScan I for assessing suspected cervical abnormalities in people having colposcopy

Diagnostics guidance Published April 2018

Tests in secondary care to identify people at high risk of ovarian cancer (DG31)

Evidence-based recommendations on tests (IOTA ADNEX, Overa, RMI I, ROMA, IOTA Simple Rules) in secondary care to identify people at high risk of ovarian cancer

Diagnostics guidance Published November 2017

Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care (DG30)

Evidence-based recommendations on quantitative faecal immunochemical tests (OC Sensor, HM-JACKarc and FOB Gold) to guide GP referral for colorectal cancer

Diagnostics guidance Published July 2017

Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive, ARCHITECT STAT High Sensitive Troponin-I and AccuTnI+3 assays) (DG15)

Evidence-based recommendations on high-sensitivity troponin tests for the early rule-out of acute myocardial infarction (AMI)

Diagnostics guidance Published October 2014

Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) (DG14)

Evidence-based recommendations on point-of-care coagulometers (the CoaguChek XS system) to self-monitor blood clotting

Diagnostics guidance Published September 2014 Last updated December 2017

Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath (DG12)

Evidence-based recommendations on the NIOX MINO, NIOX VERO and Nobreath devices to measure fractional exhaled nitric oxide concentration in asthma

Diagnostics guidance Published April 2014

Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (DG11)

Evidence-based recommendations on faecal calprotectin diagnostic tests for inflammatory diseases of the bowel

Diagnostics guidance Published October 2013

The EOS 2D/3D imaging system (DG1)

Evidence-based recommendations on the EOS 2D/3D imaging system for radiological examinations

Diagnostics guidance Published October 2011

Rapid tests for group A streptococcal infections in people with a sore throat (DG38)

Evidence-based recommendations on rapid tests for group A streptococcal (strep A) infections in people aged 5 and over with a sore throat

Diagnostics guidance Published November 2019

Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (DG13)

Evidence-based recommendations on viscoelastometric point-of-care testing (ROTEM, TEG and Sonoclot systems) to detect, manage and monitor haemostasis

Diagnostics guidance Published August 2014

Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (DG8)

Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in breast cancer

Diagnostics guidance Published August 2013

EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)

Evidence-based recommendations on EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (NSCLC)

Diagnostics guidance Published August 2013

Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)

Evidence-based recommendations on the My5-FU assay for guiding dose adjustment for fluorouracil chemotherapy

Diagnostics guidance Published December 2014

Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast (DG37)

Evidence-based recommendations on point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast

Diagnostics guidance Published November 2019

Tacrolimus and pimecrolimus for atopic eczema (TA82)

Evidence-based recommendations on non-steroidal tacrolimus and pimecrolimus for treating atopic eczema (atopic dermatitis)

Technology appraisal guidance Published August 2004

Frequency of application of topical corticosteroids for atopic eczema (TA81)

Evidence-based recommendations on the frequency of application of topical corticosteroids for treating atopic eczema (atopic dermatitis)

Technology appraisal guidance Published August 2004

Fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding (TA78)

Evidence-based recommendations on fluid-filled thermal balloon and microwave endometrial ablation techniques for treating heavy menstrual bleeding (HMB)

Technology appraisal guidance Published April 2004

Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia (TA77)

Evidence-based recommendations using zolpidem and zopiclone (the Z-drugs) for the short-term management of insomnia (sleeplessness) in adults

Technology appraisal guidance Published April 2004

Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (TA75)

Evidence-based recommendations on interferon alfa (pegylated and non-pegylated) and ribavirin for treating chronic hepatitis C

Technology appraisal guidance Published January 2004 Last updated November 2013

Pre-hospital initiation of fluid replacement therapy in trauma (TA74)

Evidence-based recommendations on giving intravenous (IV) fluid replacement therapy for people with serious injuries before reaching hospital

Technology appraisal guidance Published January 2004

Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction (TA73)

Evidence-based recommendations on myocardial perfusion scintigraphy (MPS) for diagnosing and managing angina and myocardial infarction (MI)

Technology appraisal guidance Published November 2003 Last updated July 2011

Guidance on the use of coronary artery stents (TA71)

Evidence-based recommendations on coronary artery stents for treating coronary artery disease (CAD)

Technology appraisal guidance Published October 2003 Last updated July 2008

Guidance on the use of imatinib for chronic myeloid leukaemia (TA70)

Evidence-based recommendations on imatinib (Glivec) for treating chronic myeloid leukaemia (CML)

Technology appraisal guidance Published October 2003 Last updated January 2016

Guidance on the use of liquid-based cytology for cervical screening (TA69)

Evidence-based recommendations on liquid-based cytology (LBC) for cervical screening

Technology appraisal guidance Published October 2003

Human growth hormone (somatropin) in adults with growth hormone deficiency (TA64)

Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humantrope, Norditropin, Saizen) in adults with growth hormone deficiency

Technology appraisal guidance Published August 2003

Dapagliflozin with insulin for treating type 1 diabetes (TA597)

Evidence-based recommendations on dapagliflozin (Forxiga) with insulin for type 1 diabetes not controlled by insulin therapy alone in adults with a BMI of at

Technology appraisal guidance Published August 2019

Risankizumab for treating moderate to severe plaque psoriasis (TA596)

Evidence-based recommendations on risankizumab (Skyrizi) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published August 2019

Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)

Evidence-based recommendations on dacomitinib (Vizimpro) for locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published August 2019

Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) (TA594)

NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin (Adcetris) for untreated advanced Hodgkin lymphoma in adults

Technology appraisal guidance Published August 2019

Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593)

Evidence-based recommendations on ribociclib (Kisqali) for hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in adults

Technology appraisal guidance Published August 2019

Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592)

Evidence-based recommendations on cemiplimab (Libtayo) for treating locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC) in adults

Technology appraisal guidance Published August 2019

Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)

Evidence-based recommendations on letermovir (Prevymis) for preventing cytomegalovirus (CMV) disease after a stem cell transplant in adults

Technology appraisal guidance Published July 2019

Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)

Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for treating recurrent non-infectious uveitis in adults

Technology appraisal guidance Published July 2019

Guidance on the use of electroconvulsive therapy (TA59)

Evidence-based recommendations on electroconvulsive therapy (ECT) for treating severe depressive illness, mania and catatonia

Technology appraisal guidance Published April 2003 Last updated October 2009

Nusinersen for treating spinal muscular atrophy (TA588)

Evidence-based recommendations on nusinersen (Spinraza) for treating spinal muscular atrophy in children and adults

Technology appraisal guidance Published July 2019

Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)

Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for previously untreated multiple myeloma in adults

Technology appraisal guidance Published June 2019

Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)

Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults

Technology appraisal guidance Published June 2019

Ocrelizumab for treating primary progressive multiple sclerosis (TA585)

Evidence-based recommendations on ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (MS) in adults

Technology appraisal guidance Published June 2019

Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)

Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous NSCLC

Technology appraisal guidance Published June 2019

Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) (TA582)

NICE is unable to make a recommendation about the use in the NHS of cabozantinib (Cometriq) for previously treated advanced hepatocellular carcinoma in adults

Technology appraisal guidance Published May 2019

Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA581)

Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma in adults

Technology appraisal guidance Published May 2019

Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61)

Evidence-based recommendations on capecitabine for treating metastatic colorectal cancer in adults

Technology appraisal guidance Published May 2003